Plant-Derived EV Platform — Rose & Marine-Fermented Fractions, Characterized Like Pharma Intermediates

The problem this playbook solves: plant-derived exosome storytelling is everywhere and documentation is nowhere — brands want the origin narrative with a real material chain behind it.

01 · The problem

Plant-derived EVs are the trend narrative of the category — rose, ginseng, green tea — and the least documented: most offers are extracts with an exosome name and no measurement discipline. Brands want the origin story for the shelf and the filing, and cannot find a supplier who treats plant EVs with the same characterization rigor as pharmaceutical intermediates.

02 · Scientific rationale

TONGNIAN's platform runs plant fractions (rose-derived, marine-fermented) through the same characterization baseline as animal-source EVs: NTA sizing, TEM morphology, endotoxin and microbial panels, batch COA [2][5]. Gentle handling and compliant phrasing are native to the closed micro-batch line, matching published plant-EV carrier guidance [4]. The result: origin storytelling that survives a diligence pass.

03 · Program documentation

Plant platform documentation is maintained internally — extraction records, characterization baseline, and formulation compatibility notes [7]. [6]

Method anchors: [1] EV biology and cargo [2] MISEV2018 characterization [3] category evidence (review or registered study) [4] formulation and handling guidance [5] national measurement guideline (2026 No. 17) [6] internal protocol and case documentation.

04 · Product architecture

05 · Process & QC

EV material runs on the fully enclosed 0.5–5 L micro-batch line with low-shear handling qualified at process validation [4]. QC panel design follows MISEV2018 [2] and the national measurement guideline (2026 No. 17, TONGNIAN a drafting organization) [5].

Fig. 1 — The plant platform map: fractions, sources, format roles.

06 · Regulatory pathway: EU & US first

EU: Regulation (EC) No 1223/2009 — CPNP notification, Responsible Person, PIF/CPSR. US: MoCRA (2022) registration and listing; INCI labelling (41316). Appearance-level claims only per EU Reg. 655/2013 and US advertising standards. China market entry later maps to the CSAR track — additional market. Plant-origin wording follows cosmetic claim criteria; no pesticidal, therapeutic, or novel-food implications claimed without assessment.

07 · Expected outcomes

• Origin story backed by data: plant narrative plus batch measurement — the combination the shelf lacks.
• Cross-line leverage: fractions serve skincare, intimate care, and oral families.
• Compliance path cleared on both EU and US cosmetic frameworks.

No claims are made beyond the destination-market framing — authority comes from documentation and batch measurement.

08 · Commercial framework

Sample kits in 3–5 days; pilot from 500 units; production from 2,000 units; standard lead 15 workdays — all indicative, quoted per request. White-label runs through the OBM program.

Request a quote · Line fact-sheet

References

1. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.
2. Théry C, et al. MISEV2018. J Extracell Vesicles. 2018;7(1):1535750.
3. Grand Ingredients. Exosome-Mimetic Systems 2026; cargo-handling reference.
4. Cobetter. Exosomes Part I: Applications and Downstream Processing Overview. Technical review, 2025.
5. TONGNIAN. Rose-derived plant EV platform documentation (internal).
6. Guideline for Exosome Particle Size and Concentration Measurement (2026 No. 17) — TONGNIAN, drafting organization.